Retatrutide Release Date: When Will It Be Available?

There's no retatrutide release date yet, but there is a filing date: Lilly plans to submit retatrutide to the FDA in Q1 2027. Run the FDA's own review clock from there and a US approval most likely lands between January and March 2028, or in September to November 2027 if the FDA grants a priority review. As of September 2026, no version of retatrutide is approved anywhere, and Lilly says it's legally available only to people in its trials.

The dates below come from Lilly's own announcements and the FDA's published review goals. Where a date is our arithmetic, we show the working so you can check it.

What Lilly has said about the retatrutide release date

Lilly hasn't named a launch date. What it has said, in its July 23, 2026 release on TRIUMPH-2 and TRIUMPH-3, is that it's finishing the chemistry, manufacturing and controls (CMC) data package needed for a Biologics License Application and "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval." CMC is the part of an application that proves the company can make the drug the same way, batch after batch. The clinical side is done: Lilly says it "now [has] the clinical data package to support global submissions" for obesity, knee osteoarthritis pain and obstructive sleep apnea.

Lilly's public FAQ, last updated July 2026, says "Retatrutide is not yet available for public use," and that launch "will depend on the completion of these trials and the regulatory approval process."

The TRIUMPH Phase 3 program began in 2023 and has enrolled more than 5,800 people, according to Lilly's TRIUMPH-1 release. Five Phase 3 trials have reported since December 2025. This is the path so far, with what's scheduled next:

If you've seen threads on r/Retatrutide announcing a "2027 release", they're mostly repeating the filing date. A filing starts the FDA's review. It doesn't end it. For the approval process in more depth, see is retatrutide FDA approved.

How the FDA clock turns a 2027 filing into a 2028 date

The FDA's review goals for new drugs are public. Under the current user fee agreement (PDUFA VII), which covers original Biologics License Applications received through September 30, 2027, the FDA aims to act on 90% of standard applications "within 10 months of the 60-day filing date," and on 90% of priority applications within 6 months of that date. The 60-day filing date is when the FDA confirms the application is complete enough to review. So a standard review runs about 12 months from submission, and a priority review about 8 months.

Q1 2027 runs from January 1 to March 31. Here's what the goal dates look like for 3 submission days in that quarter:

A goal date is the day the FDA aims to decide, and the decision can be approval or a letter asking for more. The FDA tells the company which track it's on after it accepts the filing, so nobody outside Lilly and the FDA will know the review type before spring 2027 at the earliest.

Our read: plan around the standard-review column. Priority review is meant for drugs that would be a big improvement for a serious condition, and there are already approved drugs for obesity, so January to March 2028 is the safer working date for a US approval.

Could it arrive faster?

Two things could pull the date forward.

The first is priority review, covered above. The FDA's own description says it goes to drugs that would bring "significant improvements in the safety or effectiveness" of treating a serious condition. Lilly could argue that 28.3% average weight loss in TRIUMPH-1 clears that bar, and the FDA gives its answer within 60 days of receiving the application.

The second is the Commissioner's National Priority Voucher, an FDA pilot launched in 2025 that targets a decision in 1 to 2 months once a complete application is in. Lilly has been through it once already. The FDA gave a voucher to orforglipron in November 2025 and approved it, as Foundayo, on April 1, 2026, 50 days after filing, by the FDA's own count. None of the voucher awards the FDA lists on its program page names retatrutide, as of September 2026. If one appears, the date in the table above could move up by most of a year. Our retatrutide news page tracks that kind of announcement.

What could push it later

Several ordinary parts of FDA review can add time:

• A major amendment. If Lilly sends a big new study report or reanalysis during the review, the FDA can extend the goal date by 3 months, once per review cycle.
• A complete response letter. The FDA can decline to approve on the first pass and list what it needs. The company then fixes the issues and resubmits, which starts a new, shorter review.
• A slip in the filing itself. Q1 2027 depends on finishing the manufacturing package, and a filing in April would move every date in the table by the same amount.

There's also a legal wrinkle. Lilly wants retatrutide classed as a biologic, and the FDA turned that request down. A federal court in Indiana set aside part of the FDA's decision in September 2025 and sent it back to the agency. Lilly appealed to the 7th Circuit in February 2026 (case 26-1301), and the court heard arguments on September 24, 2026. The classification decides whether retatrutide is regulated as a drug or as a biological product. For the release date it matters less than you'd think, because the FDA's 10-month and 6-month goals are the same for new-molecule drug applications and original biologic applications. The legal status page covers what the classification means for buying and compounding.

From FDA approval to your pharmacy

For a Lilly obesity drug, approval and availability have come close together. The FDA approved Zepbound (tirzepatide) on November 8, 2023, and Lilly announced it was in US pharmacies on December 5, 2023, 27 days later. Foundayo moved faster: approved April 1, 2026, with LillyDirect shipping from April 6 and retail pharmacies "shortly after." Those are Lilly's track records with other drugs, not a promise about retatrutide, but they're the best guide there is.

Getting it covered is a separate clock. Zepbound launched at a list price of $1,059.87, with Lilly saying the list price "does not reflect the typical out-of-pocket cost" once insurance and savings cards come in. Lilly hasn't announced any price for retatrutide; its FAQ says only that it'll be "priced to reflect the overall value to the healthcare system." Whether your plan pays for it is up to each insurer after launch, so the pharmacy date and the covered date may differ.

The first approval will also cover only what Lilly files for. Its July release names obesity, knee osteoarthritis pain and obstructive sleep apnea. Other trials are still running, including TRIUMPH-5, a head-to-head against tirzepatide with primary completion listed for November 2026, and a cardiovascular and kidney outcomes trial listed for February 2029, according to ClinicalTrials.gov. Those can add uses later without holding up the first launch.

Outside the US

Lilly hasn't published a filing date for any other country. Its July 2026 release says the data package supports "global submissions," and its orforglipron release shows how Lilly has done this lately: it filed orforglipron in more than 40 countries and said it would launch in each "shortly after approval." Each regulator runs its own review, so expect staggered dates, and Lilly hasn't said whether its first filings outside the US will go in alongside the FDA one. For the current legal position in each place, see is retatrutide legal.

Getting retatrutide before the release date

There are two legal routes, and both are narrow.

Clinical trials are the main one, but few are open. As of September 2026, ClinicalTrials.gov lists 33 retatrutide records and only 2 are recruiting: Lilly's SYNERGY-Outcomes liver study and a small study in China that Lilly doesn't run. Our clinical trials page lists which are open and how to screen.

Expanded access is the other. Lilly posted a pre-approval program in June 2026 for single patients, and the criteria on ClinicalTrials.gov are strict. You'd need all of these:

• 18 or older
• A BMI of 35 or more despite sticking with the highest available dose of an approved weight management drug
• At least 2 serious or life-threatening obesity-related complications that are being treated
• No way to join a retatrutide trial or a similar one, because you don't qualify or there's no site nearby
• A documented talk with your doctor about all standard options, including bariatric surgery

Your doctor makes the request, not you, through the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). Lilly says availability depends on location and supply. Our guide on how to get retatrutide covers both routes step by step.

Everything else sold as retatrutide is outside those routes. Lilly's FAQ says no one should take anything claiming to be retatrutide outside a Lilly trial, and that illicit products "may contain unknown ingredients, harmful contaminants and impurities" or the wrong amount. The FDA says it has warned companies selling retatrutide with labels saying it isn't for people, and that retatrutide can't be used in compounding under federal law. If you're weighing vials sold online anyway, our page on retatrutide for sale explains what those products are and how people check batch test reports.

What to watch between now and approval

The next real signal is Lilly confirming that the FDA submission has gone in. About 60 days after that, the FDA decides whether to accept the filing and sets the review type. Once Lilly says which review retatrutide got, you can read the approval window straight off the table above, give or take a 3-month extension.